Vanderbilt-Ingram Cancer Center | Strategic Alliance Partners

Latest from Vanderbilt-Ingram Cancer Center


Spotlight on a Rare Hematologic Disorder: Hereditary Hemorrhagic Telangiectasia

March 22, 2023

Hematologists and oncologists are uniquely poised to aid in the identification of patients with hereditary hemorrhagic telangiectasia and assist in their care, and it is important for the practicing clinician to familiarize oneself with the symptoms of hereditary hemorrhagic telangiectasia to avoid overlooking the diagnosis.

Investigational Treatments for Refractory RCC Expand Beyond Immunotherapy

February 23, 2023

Brian I. Rini, MD, discusses standard and investigational treatment options for patients with RCC who are refractory to immunotherapy; the potential role of biomarkers in future targeted treatments; and the need for novel mechanisms such as HIF inhibition to meet the needs of patients who don’t respond to immunotherapy or VEGF TKIs.